Voxzogo 0.4mg Kit
Product Images NDC 68135-082

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Voxzogo 0.4mg (NDC 68135-082). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biomarin Pharmaceutical Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Voxzogo 01)

FDA Label Image

Image (Voxzogo 02)

This text lacks context to provide a description. It seems to be related to some sort of medication in the form of a powder, and there is mention of a cap, vial stopper, and vial, but without additional information, it is not possible to provide a useful description.*

FDA Label Image

Image (Voxzogo 03)

FDA Label Image

Image (Voxzogo 04)

This appears to be a description of a needle labeled as "Diluent Needle" with a blue tab needle cap that has a retractable needle. The text also mentions that the needle is "safe" but it's not clear what that means without more context.*

FDA Label Image

Image (Voxzogo 05)

A container designed for the safe disposal of sharp objects and needles, typically used in medical or laboratory settings.*

FDA Label Image

Image (Voxzogo 06)

This is a prefilled syringe containing diluent with a plunger rod cap. It is meant to be used with BMN-111 and sterile water is used to reconstitute it.*

FDA Label Image

Image (Voxzogo 07)

FDA Label Image

Image (Voxzogo 08)

This appears to be a basic description of an injection syringe, including components such as the needle, needle cap, plunger rod, and a reference to the needle being inside.*

FDA Label Image

Step 1 (Voxzogo 09)

This text is a warning about avoiding touching the stopper of a vial after wiping it with an alcohol pad.*

FDA Label Image

Step 2 (Voxzogo 10)

FDA Label Image

Step 3 (Voxzogo 11)

FDA Label Image

Step 4 (Voxzogo 12)

FDA Label Image

Step 5 (Voxzogo 13)

This text seems to be a cautionary message instructing users to avoid touching the needle tip and to press the blue tab to retract the needle. The character '¢' may have been a symbol representing a certain action but could not be interpreted due to errors.*

FDA Label Image

Step 6 (Voxzogo 14)

The text is not-readable and contains many typos.*

FDA Label Image

Step 7 (Voxzogo 15)

FDA Label Image

Step 8 (Voxzogo 16)

The text provides some brief instructions about handling a vial, warning the reader to be cautious not to bend the needle while doing so. It is not clear what specific context or situation these instructions refer to.*

FDA Label Image

Step 9 (Voxzogo 17)

FDA Label Image

Step 10 (Voxzogo 18)

FDA Label Image

Step 11 (Voxzogo 19)

This text provides instructions on two important aspects of administering medication, namely, removing bubbles from the syringe and measuring the prescribed dose accurately. It advises the reader to remove any large bubbles from the syringe and states that some small bubbles are acceptable. Additionally, it emphasizes the importance of ensuring that the dose in the syringe matches the prescribed dose.*

FDA Label Image

Step 12 (Voxzogo 20)

FDA Label Image

Step 13 (Voxzogo 21)

This text gives instructions about proper injection sites for Voxzogo. It advises against injecting through clothes or into skin that is swollen, sore, bruised, or scared. The recommended injection sites are thighs (not through clothes), abdomen (2 inches from belly button), buttocks, and the back of the upper arms. This text may be useful for healthcare providers or caregivers administering Voxzogo injections.*

FDA Label Image

Step 14 (Voxzogo 22)

FDA Label Image

Step 15 (Voxzogo 23)

FDA Label Image

Step 16 (Voxzogo 24)

FDA Label Image

Step 17 (Voxzogo 25)

FDA Label Image

Step 17 (Voxzogo 26)

FDA Label Image

Image (Voxzogo 27)

FDA Label Image

Step 18 (Voxzogo 28)

FDA Label Image

Principal Display Panel (Kit Carton)

FDA Label Image

Principal Display Panel (0.4 mg Vial Label)

This is a pharmaceutical label for a single-dose vial with the drug code MLC7246800. The label advises to reconstitute prior to use and that it is for subcutaneous use only. The drug is available only by prescription. The label also includes a LOT and EXP number for tracking the drug's expiration date.*

FDA Label Image

Principal Display Panel (0.5 mL Syringe Label)

This is a description for the drug diluent used for VOXZOGOTM injection. It should only be used for dilution as directed and is single-dose with no preservatives. The product is distributed by BioMarin and includes a lot number and expiration date.*

FDA Label Image

Principal Display Panel (Kit Carton)

FDA Label Image

Principal Display Panel (0.56 mg Vial Label)

FDA Label Image

Principal Display Panel (0.7 mL Syringe Label)

This is a drug diluent for VOXZOGOT™ for Injection, with NDC code 68135-102-43 and is distributed by BioMarin. It is a single-dose diluent with no preservative and must be reconstituted as directed. The lot number is 10008843-02 with an expiration date (EXP) that is not available in the given text.*

FDA Label Image

Principal Display Panel (Kit Carton)

FDA Label Image

Principal Display Panel (1.2 mg Vial Label)

This is a medication called VOXZOoGOo™ or vosoritide, which is available in a single-dose vial for subcutaneous injection only. The vial contains 1.2 mg of the medication, and it needs to be reconstituted before use. It is manufactured by a company called BioMarin.*

FDA Label Image

Principal Display Panel (0.6 mL Syringe Label)

This is a description of a diluent for VOXZOGOTM injection. It is available by prescription only and should only be used as a drug diluent. The diluent is single-dose and does not contain any preservatives. It is distributed by BioMarin and comes with a lot and expiration number.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.